SAM
IONS icon

SEB Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

SEB Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.07M Hold
114,334
– – 0.03% 358
2026
Q1 		$8.59M Buy
+114,334
New +$9.02M 0.04% 344

Other funds holding IONS

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SEB Asset Management's IONS Position: Q2 2026 in Review

SEB Asset Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 114,334 shares worth $9.07M. The position accounts for 0.03% of the portfolio, ranked #358.

SEB Asset Management first reported a position in IONS in Q1 2026 and has held it in 2 quarters since. 477 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • SEB Asset Management held 114,334 shares of Ionis Pharmaceuticals worth $9.07M as of Q2 2026.
  • SEB Asset Management left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up 0.03% of SEB Asset Management's portfolio in Q2 2026, its #358 holding.
  • SEB Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 477 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.